Clinical Trial Update: 16-week Flexible vs. 8-week Semaglutide Titration [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing 16-week flexible versus 8-week titration of semaglutide for type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Diabetes type2 | Phase 3 | Status: UNKNOWN